Vertex Pharmaceuticals Incorporated (LON:0QZU)

London flag London · Delayed Price · Currency is GBP · Price in USD
416.83
-3.15 (-0.75%)
At close: Oct 29, 2025
-0.75%
Market Cap80.80B
Revenue (ttm)8.33B
Net Income (ttm)2.66B
Shares Outn/a
EPS (ttm)10.27
PE Ratio30.43
Forward PE21.40
Dividendn/a
Ex-Dividend Daten/a
Volume334
Average Volume444
Open420.00
Previous Close419.98
Day's Range416.21 - 423.00
52-Week Range362.50 - 519.68
Beta0.43
RSI54.64
Earnings DateNov 3, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1989
Employees 6,100
Stock Exchange London Stock Exchange
Ticker Symbol 0QZU
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

JEPQ, ADI, VRTX, ORLY: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the JPMorgan Nasdaq Equity Premium Income ETF (Symbol: JEPQ) where we have...

6 days ago - Nasdaq

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators...

7 days ago - Business Wire

Insiders Bullish on Certain Holdings of JDOC

A look at the weighted underlying holdings of the JPMorgan Healthcare Leaders ETF (JDOC) shows an impressive 11.8% of holdings on a weighted basis have experienced insider buying within the past six m...

8 days ago - Nasdaq

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

8 days ago - Nasdaq

ClearBridge Select Strategy buys REGN, VRTX & VST; exits ICLR, PCTY & ADBE

Discover how ClearBridge Select Strategy outperformed major indices in Q3 2025 and see the key stock moves driving future portfolio growth.

9 days ago - Seeking Alpha

Vertex Pharmaceuticals (VRTX) Advances Povetacicept for Kidney Disease Treatment

Vertex Pharmaceuticals (VRTX) Advances Povetacicept for Kidney Disease Treatment

13 days ago - GuruFocus

Vertex Pharmaceuticals (VRTX) Advances Development of Key Therapeutic

Vertex Pharmaceuticals (VRTX) Advances Development of Key Therapeutic

13 days ago - GuruFocus

Vertex IgA nephropathy asset povetacicept granted FDA rolling review

Vertex Pharmaceuticals receives FDA rolling review for its IgA nephropathy drug candidate povetacicept. Read more here.

13 days ago - Seeking Alpha

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal developme...

13 days ago - Benzinga

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombi...

13 days ago - Business Wire

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $407.9, denoting a -1.05% move from the preceding trading day.

15 days ago - Nasdaq

Vertex Pharmaceuticals (VRTX): Analyst Rating Update from Morgan Stanley | VRTX Stock News

Vertex Pharmaceuticals (VRTX): Analyst Rating Update from Morgan Stanley | VRTX Stock News

20 days ago - GuruFocus

VRTX: JP Morgan Raises Price Target to $530 | VRTX Stock News

VRTX: JP Morgan Raises Price Target to $530 | VRTX Stock News

22 days ago - GuruFocus

Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on Vertex Pharmaceuticals . Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If w...

22 days ago - Benzinga

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

22 days ago - Nasdaq

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The com...

24 days ago - Business Wire

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years

Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 20 years by 6.5% on an annualized basis producing an average annual return of 15.61%. Currently, Vertex Pharmaceuticals...

24 days ago - Benzinga

Noteworthy ETF Outflows: VUG, SYK, BX, VRTX

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Growth ETF (Symbol: VUG) where we have detected an approximat...

24 days ago - Nasdaq

Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuticals Inc (VRTX)

Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuticals Inc (VRTX)

27 days ago - GuruFocus

Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $403.3, indicating a -1.36% shift from the previous trading day.

27 days ago - Nasdaq

ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'

On CNBC's “ Halftime Report Final Trades ,” on Thursday, Jason Snipe , founder and chief investment officer of Odyssey Capital Advisors, said he likes ServiceNow, Inc. (NYSE: NOW), which is down 14% ...

27 days ago - Benzinga

Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $408.85, representing a +1.15% change from its previous close.

4 weeks ago - Nasdaq

Vertex Pharmaceuticals (VRTX) Receives Raised Price Target from Citigroup | VRTX Stock News

Vertex Pharmaceuticals (VRTX) Receives Raised Price Target from Citigroup | VRTX Stock News

4 weeks ago - GuruFocus

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

CNBC's “Halftime Report” team discuss their top stocks and final trades.

4 weeks ago - CNBC Television

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

CNBCs Halftime Report team discuss their top stocks and final trades.

4 weeks ago - CNBC